Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

Tiffany A. Traina, MD
Published: Monday, Mar 19, 2018



Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

The prevalence of germline BRCA mutations is difficult to fully understand because physicians are not clear what the ultimate denominator is. The data presented at the 2017 San Antonio Breast Cancer Symposium showed that there are patients who should undergo clinical genetic testing so they can be aware of their germline BRCA status, says Traina.

The data prior to the conference was related to the PARP inhibitor olaparib (Lynparza). Data from the OlympiAD study revealed single-agent olaparib oral therapy was superior to physicians' choice of chemotherapy. That arm included capecitabine, eribulin (Halaven), or vinorelbine. Olaparib had about a 40% improvement in median progression-free survival for women with germline BRCA mutations with metastatic disease. The safety profile was very tolerable relative to cytotoxic chemotherapy.
 
SELECTED
LANGUAGE


Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

The prevalence of germline BRCA mutations is difficult to fully understand because physicians are not clear what the ultimate denominator is. The data presented at the 2017 San Antonio Breast Cancer Symposium showed that there are patients who should undergo clinical genetic testing so they can be aware of their germline BRCA status, says Traina.

The data prior to the conference was related to the PARP inhibitor olaparib (Lynparza). Data from the OlympiAD study revealed single-agent olaparib oral therapy was superior to physicians' choice of chemotherapy. That arm included capecitabine, eribulin (Halaven), or vinorelbine. Olaparib had about a 40% improvement in median progression-free survival for women with germline BRCA mutations with metastatic disease. The safety profile was very tolerable relative to cytotoxic chemotherapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x